No specific investigations were done to analyse other causes of anemia because its onset was expected after natalizumab treatment, as reported in the current literature [11]; moreover, there were not risk obstetrics factors sustaining the anemia onset in the newborn; lastly, the response to EPO therapy increases the evidence that the anemia was subsequent to natalizumab therapy and seems to exclude several other etiologies. Here, EPO is linked to anemia.